FGFR3 fusion with transforming acidic coiled-coil-containing protein 3 (TACC3) (FGFR-TACC3) has been characterized and correlated with a more aggressive phenotype in malignancies such as glioblastoma and head and neck cancers, for which no effective therapeutic option is still available [9]. Here, TACC3 is linked to glioblastoma.